GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CASI Pharmaceuticals Inc (NAS:CASI) » Definitions » Price-to-Tangible-Book

CASI Pharmaceuticals (CASI Pharmaceuticals) Price-to-Tangible-Book : 1.46 (As of Apr. 26, 2024)


View and export this data going back to 1996. Start your Free Trial

What is CASI Pharmaceuticals Price-to-Tangible-Book?

As of today (2024-04-26), CASI Pharmaceuticals's share price is $2.4445. CASI Pharmaceuticals's Tangible Book per Share of Dec. 2023 for the quarter that ended in Dec. 2023 was $1.67. Hence, CASI Pharmaceuticals's Price to Tangible Book Ratio of today is 1.46.

The historical rank and industry rank for CASI Pharmaceuticals's Price-to-Tangible-Book or its related term are showing as below:

CASI' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.55   Med: 4.26   Max: 5.89
Current: 1.46

During the past 13 years, CASI Pharmaceuticals's highest Price to Tangible Book Ratio was 5.89. The lowest was 0.55. And the median was 4.26.

CASI's Price-to-Tangible-Book is ranked better than
74.84% of 1220 companies
in the Biotechnology industry
Industry Median: 2.68 vs CASI: 1.46

A closely related ratio is called PB Ratio. As of today, CASI Pharmaceuticals's share price is $2.4445. CASI Pharmaceuticals's Book Value per Sharefor the quarter that ended in Dec. 2023 was $1.81. Hence, CASI Pharmaceuticals's P/B Ratio of today is 1.35.


CASI Pharmaceuticals Price-to-Tangible-Book Historical Data

The historical data trend for CASI Pharmaceuticals's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CASI Pharmaceuticals Price-to-Tangible-Book Chart

CASI Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Tangible-Book
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.09 5.35 1.55 0.55 4.29

CASI Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Tangible-Book Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.55 0.80 1.05 1.20 4.29

Competitive Comparison of CASI Pharmaceuticals's Price-to-Tangible-Book

For the Biotechnology subindustry, CASI Pharmaceuticals's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CASI Pharmaceuticals's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CASI Pharmaceuticals's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where CASI Pharmaceuticals's Price-to-Tangible-Book falls into.



CASI Pharmaceuticals Price-to-Tangible-Book Calculation

CASI Pharmaceuticals's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book=Share Price/Tangible Book per Share (Q: Dec. 2023 )
=2.4445/1.669
=1.46

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.


CASI Pharmaceuticals Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of CASI Pharmaceuticals's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.


CASI Pharmaceuticals (CASI Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
9620 Medical Center Drive, Suite 300, Rockville, MD, USA, 20850
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing innovative therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA. The company primarily operates in the United States, Canada, China and other parts of the world.
Executives
James Huang director 9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850
Wei-wu He director, 10 percent owner, officer: Chairman and CEO ENTREMED, INC., 9640 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Weihao Xu officer: Chief Financial Officer 9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850
Larry Zhang officer: President 9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850
Shrotriya Rajesh C Md director 157 TECHNOLOGY DRIVE, IRVINE CA 92618
Salisbury Franklin Cary Jr director 9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850
Yue Alexander Wu director C/O SORRENTO THERAPEUTICS, INC., 9380 JUDICIAL DRIVE, SAN DIEGO CA 92121
Wealth Strategy Holding Ltd 10 percent owner LEVEL 12, INTERNATIONAL COMMERCE CENTRE, 1 AUSTIN ROAD WEST, HONG KONG K3 HK
Alexander A Zukiwski officer: Chief Medical Officer 200 ROUTE 31 NORTH, SUITE 104, FLEMINGTON NJ 08822
George Chi officer: Chief Financial Officer 9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850
Dapeng Li 10 percent owner BUILDING 1037,XIHU GOLF,, ZHIGANG ROAD 200, HANGZHOU, ZHEJANG F4 310008
Idg-accel China Growth Fund Iii L.p. 10 percent owner UNIT 5505, 55TH FLOOR, THE CENTER, 99 QUEEN'S ROAD K3 00000
Spectrum Pharmaceuticals Inc 10 percent owner 11500 S. EASTERN AVE., SUITE 240, HENDERSON NV 89052
Sparkle Byte Ltd 10 percent owner P.O. BOX 957, OFFSHORE INCORPORATIONS CENTRE ROAD TOWN, TORTOLA D8 00000
Ken Ren director, officer: CEO and Director 3RD FL, BOROUGH A, BLOCK A, NO. 181 SOUTH TAIBAI ROAD, XI'AN, SHAANXI PROVINCE F4 710065